Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
주식 순위 #33300
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
주가
$0.4264
마지막 동기화: 2022-09-14
시가총액
$7.93M
변동 (1일)
-16.44%
변동 (1년)
0.00%
국가
US
거래 Caladrius Biosciences, Inc. (CLBS)

카테고리

Caladrius Biosciences, Inc. (CLBS)의 배당 수익률 기록
Caladrius Biosciences, Inc. (주식 심볼: CLBS)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Caladrius Biosciences, Inc. (CLBS)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)